Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
20 pending office actions • 9 art units • 18 examiners • 0 of 20 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Hanmi Pharm. Co., Ltd. manages a portfolio with 20 pending office actions in the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 18 distinct examiners and 9 distinct art units. The high count of 9 art units reflects a broad range of pharmaceutical sub-specialties being pursued by the company. YANG, TIAN is identified as the busiest examiner, holding 2 pending office actions.
With 18 distinct examiners for 20 actions, the company faces a wide variety of individual examination styles. This distribution across 9 art units requires a versatile prosecution strategy to handle the different standards and practices of each group. The relatively low concentration of actions per examiner suggests that no single individual has a dominant influence over the portfolio's outcome. Practitioners must coordinate across many different art units to ensure consistency in their pharmaceutical patent strategy. This breadth of examiners requires a highly organized approach to managing the company's intellectual property.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §101 + other | 1 (5%) |
| §103 only | 5 (25%) |
| §112 only | 1 (5%) |
| Double-patenting + other | 7 (35%) |
| Multi-statute (no §101) | 5 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YANG, TIAN | 2 | — | — |
| JONES-FOSTER, ERICA NICOLE | 2 | 48.1% | +44.7% |
| SHIM, DAVID M. | 1 | 58.3% | +58.3% |
| CRAIGO, WILLIAM A | 1 | 49.2% | +38.2% |
| ARMSTRONG, SUSANNAH SIPPLE | 1 | 30.0% | +53.1% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| PRIEST, JESSICA MARIE | 1 | — | — |
| WEDDINGTON, KEVIN E | 1 | 75.2% | +9.8% |
| DRISCOLL, MAUREEN VARINA | 1 | 63.7% | +40.8% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | SABILA, MERCY HELLEN | 22d |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | KONOPELSKI SNAVEL, SARA ELIZABETH | 22d |
| 18573657 | NON-NATURAL 5'-UNTRANSLATED REGION AND 3'-UNTRANSLATED REGION AND USE THEREOF | BRETZ, COREY LANE | — |
| 18573370 | EFPEGLENATIDE TO REDUCE RISK OF DEVELOPING CARDIOVASCULAR DISEASE OR RENAL DYSFUNCTION | PRIEST, JESSICA MARIE | — |
| 18554236 | COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR | YANG, TIAN | — |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | — |
| 18028348 | THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST ACTING ON ALL OF GLUCAGON, GLP-1 AND GIP RECEPTORS AGAINST MULTIPLE SCLEROSIS | YANG, TIAN | — |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | SCHMITT, MICHAEL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036538 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | 36d overdue |
| 18696960 | PIKFYVE KINASE INHIBITOR | SHIM, DAVID M. | — |
| 18832725 | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | CRAIGO, WILLIAM A | — |
| 18714147 | METHOD FOR PREPARING ORAL COMPOSITE TABLET CONTAINING PROTON PUMP INHIBITOR AND ANTACID AND ORAL COMPOSITE TABLET PREPARED THEREBY | ARMSTRONG, SUSANNAH SIPPLE | — |
| 18565628 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | DRISCOLL, MAUREEN VARINA | — |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | — |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1674 | 3 |
| 1629 | 2 |
| 1656 | 2 |
| 1615 | 2 |
| 1654 | 2 |
| 1616 | 1 |
| 1646 | 1 |
| 1619 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696960 | PIKFYVE KINASE INHIBITOR | SHIM, DAVID M. | — | §112 | Non-Final OA | — | Pending | Oct 02, 2024 |
| 18832725 | LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A | CRAIGO, WILLIAM A | — | §103§112DP | Non-Final OA | — | Pending | Jul 24, 2024 |
| 18714147 | METHOD FOR PREPARING ORAL COMPOSITE TABLET CONTAINING PROTON PUMP INHIBITOR AND ANTACID AND ORAL COMPOSITE TABLET PREPARED THEREBY | ARMSTRONG, SUSANNAH SIPPLE | 1616 | §103DP | Non-Final OA | — | Pending | May 29, 2024 |
| 18573657 | NON-NATURAL 5'-UNTRANSLATED REGION AND 3'-UNTRANSLATED REGION AND USE THEREOF | BRETZ, COREY LANE | — | §103§112DP | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18573370 | EFPEGLENATIDE TO REDUCE RISK OF DEVELOPING CARDIOVASCULAR DISEASE OR RENAL DYSFUNCTION | PRIEST, JESSICA MARIE | — | §103§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18251827 | PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA COMPRISING FLT3 INHIBITOR | WEDDINGTON, KEVIN E | 1629 | §102§103DP | Final Rejection | 13d | Pending | Dec 12, 2023 |
| 18565628 | THERAPEUTIC USE OF COMBINATION INCLUDING TRIPLE AGONIST HAVING ACTIVITIES TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | DRISCOLL, MAUREEN VARINA | — | §103§112DP | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18554236 | COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR | YANG, TIAN | 1674 | §102§103§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18036580 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | 1656 | §101 | Final Rejection | — | Pending | May 11, 2023 |
| 18036538 | USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF NEUROPATHY CAUSED BY OR ACCOMPANIED BY FABRY DISEASE | JONES-FOSTER, ERICA NICOLE | 1656 | §103 | Final Rejection | 36d overdue | Pending | May 11, 2023 |
| 18028348 | THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST ACTING ON ALL OF GLUCAGON, GLP-1 AND GIP RECEPTORS AGAINST MULTIPLE SCLEROSIS | YANG, TIAN | 1674 | §102§103§112 | Non-Final OA | — | Pending | Mar 24, 2023 |
| 18040869 | PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | CHANDRA, GYAN | 1674 | §103DP | Non-Final OA | — | Pending | Feb 07, 2023 |
| 18016165 | THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE | ROSSI, JULIA ANNE LORRAIN | 1615 | §103DP | Final Rejection | — | Pending | Jan 13, 2023 |
| 17927225 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLP-2 | PUTTLITZ, KARL J | 1646 | §103Other | Final Rejection | — | Pending | Nov 22, 2022 |
| 17915976 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY, OR COMBINATION THEREOF, COMPRISING GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE OF SAME | BRADLEY, CHRISTINA | 1654 | §103 | Final Rejection | 44d overdue | Pending | Sep 29, 2022 |
| 17915826 | ORAL COMPLEX TABLET COMPRISING SITAGLIPTIN, DAPAGLIFLOZIN, AND METFORMIN | KASSA, TIGABU | 1619 | §103 | Final Rejection | — | Pending | Sep 29, 2022 |
| 17788554 | COMPLEX FORMULATION COMPRISING SITAGLIPTIN AND DAPAGLIFLOZIN, AND PREPARATION METHOD THEREFOR | SCOTLAND, REBECCA LYNN | 1615 | §103Other | Final Rejection | — | Pending | Jun 23, 2022 |
| 17416880 | A PHARMACEUTICAL COMPOSITION COMPRISING INSULIN AND TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | SABILA, MERCY HELLEN | 1654 | §101§103§112Other | Non-Final OA | 22d | Pending | Jun 21, 2021 |
| 17282661 | THERAPEUTIC USE OF GLUCAGON AND COMBINATION INCLUDING THE SAME | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §102§103§112Other | Non-Final OA | 22d | Pending | Apr 02, 2021 |
| 17113571 | METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA | SCHMITT, MICHAEL J | 1629 | §102§103 | Final Rejection | — | Pending | Dec 07, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial